PMID- 33149758
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201106
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Therapeutic Benefit in Allergic Dermatitis Derived from the Inhibitory Effect of 
      Byakkokaninjinto on the Migration of Plasmacytoid Dendritic Cells.
PG  - 9532475
LID - 10.1155/2020/9532475 [doi]
LID - 9532475
AB  - Dendritic cells (DCs) are well known to be essential immunocytes involved in 
      innate and adaptive immunity. DCs are classified as conventional dendritic cells 
      (cDCs) and plasmacytoid dendritic cells (pDCs). Recently, the accumulation of 
      pDCs in inflamed tissues and lymphoid tissues has been considered to be a 
      possible contributing factor in the development of immunological diseases, but 
      little is known about the pathophysiological roles of pDCs in immunological 
      diseases. To date, many studies have demonstrated that many kinds of Kampo 
      formulas can regulate immunological reactions in human immune diseases. Thus, we 
      screened Kampo formulas to identify an agent that inhibits pDC migration. 
      Furthermore, we investigated the therapeutic effects of these formulas on a 
      murine DNFB-induced allergic contact dermatitis model. Bone marrow-derived pDCs 
      (BMpDCs) were derived from the bone marrow cells of BALB/c mice in a culture 
      medium with Flt3 ligand. The effects of Kampo formulas on BMpDC migration were 
      evaluated by assessing the number, velocity, and directionality of BMpDCs 
      chemotaxing toward the more concentrated side of a chemokine (C-C motif) ligand 
      21 (CCL21) gradient. The Kampo formulas that exerted inhibitory effects on pDC 
      migration were orally administered to DNFB-induced allergic contact dermatitis 
      model mice. Byakkokaninjinto reduced the number of migrated BMpDCs and suppressed 
      the velocity and directionality of BMpDC migration in a chemotaxis assay. Gypsum 
      Fibrosum and Ginseng Radix, which are components of byakkokaninjinto, obviously 
      suppressed the velocity of BMpDC migration. Furthermore, Gypsum Fibrosum 
      significantly suppressed the directionality of BMpDC migration. In DNFB-induced 
      allergic contact dermatitis model mice, byakkokaninjinto markedly abrogated ear 
      swelling in late-phase allergic reactions. In conclusions, byakkokaninjinto, 
      which has an inhibitory effect on pDC migration, was able to prevent the 
      occurrence of allergic contact dermatitis, suggesting that pDCs were involved in 
      the onset of allergic contact dermatitis in the mouse model. Therefore, 
      byakkokaninjinto is anticipated to be a therapeutic agent for disorders related 
      to pDC migration.
CI  - Copyright (c) 2020 Takeshi Yamamoto et al.
FAU - Yamamoto, Takeshi
AU  - Yamamoto T
AUID- ORCID: 0000-0002-4383-6954
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
FAU - Kigasawa, Ai
AU  - Kigasawa A
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
FAU - Hayashi, Shusaku
AU  - Hayashi S
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
FAU - Kadowaki, Makoto
AU  - Kadowaki M
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7603581
COIS- The authors declare that there are no conflicts of interest regarding the 
      publication of this article.
EDAT- 2020/11/06 06:00
MHDA- 2020/11/06 06:01
PMCR- 2020/10/22
CRDT- 2020/11/05 06:07
PHST- 2020/05/27 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/05 06:07 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/06 06:01 [medline]
PHST- 2020/10/22 00:00 [pmc-release]
AID - 10.1155/2020/9532475 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Oct 22;2020:9532475. doi: 
      10.1155/2020/9532475. eCollection 2020.